Cargando…

PK/PD modeling supports the dose-escalation decision in VIKING

Detalles Bibliográficos
Autores principales:	Lovern, M, Underwood, M, Nichols, G, Song, I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112963/ http://dx.doi.org/10.1186/1758-2652-13-S4-P182

Ejemplares similares

PK-PD correlation of anti-infective agents for dose adjustment in one severe burn child with sepsis
por: Campos, EV, et al.
Publicado: (2011)

PK/PD of single-dose amikacin in emergency department patients with severe sepsis/shock: should we apply the ICU-based higher loading dose?
por: Winter, S De, et al.
Publicado: (2015)

Alternaria alternata induced inflammatory lung responses: a novel in vivo PK/PD model
por: Gil, Malgorzata, et al.
Publicado: (2013)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

Addressing the barriers to implementing model based designs in dose escalation studies
por: Cornelius, Victoria, et al.
Publicado: (2015)

The Viking world /
por: Graham-Campbell, James
Publicado: (1980)

Some small sample properties of the EWOC design in dose escalation trials
por: Kinnersley, Nelson
Publicado: (2015)

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
por: Regan, Courtney, et al.
Publicado: (2015)

In silico pK(a) prediction
por: Körner, Robert, et al.
Publicado: (2012)

Randomized double-blind placebo-controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin Spiegelmer NOX-H94 on serum iron during experimental human endotoxemia
por: Van Eijk, L, et al.
Publicado: (2013)

Magical medicine in Viking Scandinavia.
por: Robertson, D
Publicado: (1976)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

A dose-escalation clinical trial to evaluate the safety and immunogenicity of a replication-defective HIV-1 vaccine-HIVAX
por: Tung, F, et al.
Publicado: (2012)

QSPR designer – a program to design and evaluate QSPR models. Case study on pK(a) prediction
por: Skřehota, O, et al.
Publicado: (2011)

A comparative study of in silico prediction of pK(a)
por: Matijssen, C
Publicado: (2010)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
por: Nemunaitis, John, et al.
Publicado: (2013)

Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
por: Sou, Tomás, et al.
Publicado: (2020)

A novel Bayesian method for dual-agent Phase I dose-escalation studies using penalized D-optimality
por: Wheeler, Graham
Publicado: (2013)

P267 Candida in the biliary tract: extrapolative PK PD considerations
por: Rege, Sujata, et al.
Publicado: (2022)

Dupuytren's Disease: the Vikings Disease in Koreans
por: Gong, Hyun Sik
Publicado: (2018)

De-escalation practice pattern in an Indian intensive care unit
por: Bhakta, A, et al.
Publicado: (2010)

Success of sky-polarimetric Viking navigation: revealing the chance Viking sailors could reach Greenland from Norway
por: Száz, Dénes, et al.
Publicado: (2018)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA
por: Meng, Amy, et al.
Publicado: (2021)

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
por: Grant, Joshuaine, et al.
Publicado: (2023)

Introducing VIKING: A Novel Online Platform for Multiscale Modeling
por: Korol, Vasili, et al.
Publicado: (2019)

A female Viking warrior confirmed by genomics
por: Hedenstierna‐Jonson, Charlotte, et al.
Publicado: (2017)

De-escalation therapy: 1-year experience in a general intensive care unit
por: Gyurov, E, et al.
Publicado: (2005)

A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC
por: Jonasch, Eric, et al.
Publicado: (2023)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer
por: Napoletano, Chiara, et al.
Publicado: (2013)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

De-escalation of antimicrobial therapy in Gram-negative sepsis: easier said than done?
por: Phee, L, et al.
Publicado: (2011)

Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction
por: Ahmad, Ijaz, et al.
Publicado: (2016)

PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against Streptococcus suis in Piglets
por: Huang, Anxiong, et al.
Publicado: (2022)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

Forecasting escalation of cardio-respiratory instability using noninvasive vital sign monitoring data
por: Guillame-Bert, M, et al.
Publicado: (2015)

Antibiotic costs in bacteremic and nonbacteremic patients treated with the de-escalation approach
por: Evodia, E, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_g9mevi1i6nh0mtbifmepj4pco4